FOLH1 and posterior cortical atrophy: The earlier FDA-approved PET tracers for PCa were only recommended for BCR until the emergence of PSMA-targeted tracers, which have been approved for the indication of suspected PCa metastasis before curative surgery, as well as suspected PCa recurrence.